Endogenous Peptide
Endogenous GLP-1 Is a Processed Product of Proglucagon
Endogenous glucagon-like peptide-1 is best understood through its precursor context, mature forms, receptor signaling, measurement methods, and evidence boundaries.
Educational content only. Not medical advice.
GLP-1 comes from a larger proglucagon precursor
The human GCG gene encodes preproglucagon, a 180-residue precursor containing several peptide products. Tissue-specific prohormone convertases cleave it differently, so intestinal and selected neural cells generate GLP-1-containing products while pancreatic alpha cells emphasize glucagon. Mature GLP-1 numbering refers to positions within the proglucagon-derived sequence, not a separate gene. Source, cleavage, and terminal amidation therefore belong in the identity record.
Several molecular forms appear in assays and circulation
Bioactive forms commonly include GLP-1(7-36) amide and GLP-1(7-37). Enzymatic cleavage by DPP4 produces metabolites with altered receptor activity, and kidney, liver, and tissue uptake contribute to clearance. Total GLP-1 assays and active GLP-1 assays do not measure the same pool. Pre-analytical handling and assay cross-reactivity can materially change the reported concentration.
GLP-1 receptor signaling is context-dependent
The GLP-1 receptor is a class B GPCR that can couple to cyclic AMP and other pathways. Response depends on receptor expression, glucose and nutrient context, neural and endocrine feedback, ligand kinetics, and cellular state. Endogenous secretion is meal-related and spatially organized, while a long-lived analogue creates a different exposure profile. Shared receptor activity does not make the endogenous hormone and every analogue biologically identical.
This profile is about the native system
Evidence about engineered agonists, combination agonists, or approved products should be kept on distinct pages because sequence, pharmacokinetics, selectivity, and clinical questions differ. Endogenous GLP-1 research helps explain physiology and target biology but does not provide an amount, protocol, or treatment recommendation. Claims should identify whether the measured entity was precursor, active hormone, metabolite, receptor activity, or downstream outcome.
Evidence limits
- Assays differ in recognition of active GLP-1, total GLP-1, precursors, and metabolites.
- Endogenous physiology cannot be inferred directly from pharmacological analogue studies.
- This page contains no treatment, dose, or personal-use guidance.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
UniProt Consortium
GCG - Pro-glucagon - Homo sapiens
Reviewed human precursor entry with mature GLP-1 chains, processing features, sequence, and cited functions.
Open sourceNational Center for Biotechnology Information
GCG glucagon Gene
Official human gene record linking proglucagon transcripts, proteins, references, and genomic context.
Open sourceCommon questions
Is GLP-1 encoded by its own gene?
No. It is processed from the proglucagon precursor encoded by GCG.
Are endogenous GLP-1 and long-acting analogues identical?
No. Analogues can differ in sequence, modifications, clearance, exposure, and receptor pharmacology.
Do active and total GLP-1 assays measure the same thing?
No. They can recognize different combinations of intact active forms, metabolites, and precursor-related material.
Continue with context
Continue in the evidence workspace
Explore the complete PeptideSchool research workspace to organize sources, compare evidence layers, and follow related peptide science. Premium tools remain educational and do not provide individualized medical guidance.